Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2509 | Making Mindfulness Matter© (M3) Wiki | 0.45 |
drug528 | BMS-986337 Placebo Wiki | 0.45 |
drug839 | COVID-19 swap test PCR Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D012640 | Seizures NIH | 0.77 |
D004827 | Epilepsy NIH | 0.63 |
D000070627 | Chronic Traumatic Encephalopathy NIH | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D005879 | Tourette Syndrome NIH | 0.45 |
D001714 | Bipolar Disorder NIH | 0.32 |
D006526 | Hepatitis C NIH | 0.26 |
D000690 | Amyotrophic Lateral Sclerosis NIH | 0.22 |
D000755 | Anemia, Sickle Cell NIH | 0.22 |
D003072 | Cognition Disorders NIH | 0.22 |
D016472 | Motor Neuron Disease NIH | 0.22 |
D005356 | Fibromyalgia NIH | 0.20 |
D009422 | Nervous System Diseases NIH | 0.20 |
D001927 | Brain Diseases NIH | 0.18 |
D000070642 | Brain Injuries, Traumatic NIH | 0.15 |
D015212 | Inflammatory Bowel Diseases NIH | 0.15 |
D010300 | Parkinsonian NIH | 0.13 |
D001930 | Brain Injuries, NIH | 0.12 |
D059350 | Chronic Pain NIH | 0.12 |
D003424 | Crohn Disease NIH | 0.12 |
D020521 | Stroke NIH | 0.11 |
D009103 | Multiple Sclerosis NIH | 0.10 |
D012598 | Scoliosi NIH | 0.10 |
D060825 | Cognitive Dysfunction NIH | 0.10 |
D040921 | Stress Disorders, Traumatic NIH | 0.08 |
D014947 | Wounds and Injuries NIH | 0.07 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.07 |
D004194 | Disease NIH | 0.07 |
D013577 | Syndrome NIH | 0.04 |
D003141 | Communicable Diseases NIH | 0.03 |
D007239 | Infection NIH | 0.02 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
D018352 | Coronavirus Infections NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100754 | Mania HPO | 0.32 |
HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.22 |
HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.22 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001298 | Encephalopathy HPO | 0.18 |
HP:0002037 | Inflammation of the large intestine HPO | 0.15 |
HP:0012532 | Chronic pain HPO | 0.12 |
HP:0100280 | Crohn's disease HPO | 0.12 |
HP:0001297 | Stroke HPO | 0.11 |
HP:0001268 | Mental deterioration HPO | 0.10 |
Navigate: Correlations HPO
There are 5 clinical trials
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsEpilepsy is a debilitating condition characterized by spontaneous, unprovoked seizures. Up to 80% of children with epilepsy (CWE) may face cognitive, psychiatric, and/or behavioral comorbidities with significant unmet mental health needs. Mindfulness-based interventions may provide an ideal vector to target unmet mental healthcare needs in patients with epilepsy and their families. The investigators propose the Making Mindfulness Matter© (M3) program as an intervention to improve health related quality of life and mental-health for CWE and their parents. M3 is live-online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This pilot RCT is needed to refine the implementation of the intervention to families with a child with epilepsy, and collect information pertaining to the feasibility and effectiveness of the intervention in preparation for a subsequent multi-centred trial across Canada. Note: Due to COVID-19, the format has been modified for online delivery (from community-based) and the intervention has been restarted.
Description: The investigators will track the number of patients contacted, response rate, attrition and reasons for non-participation and attrition. At the start of each session, parents will complete a one-page (12-item) semi-structured questionnaire evaluating treatment fidelity, at home utilization of M3 skills. At the end of each session, parents will complete an overall feedback form on the intervention. Facilitators will complete a two-page questionnaire providing feedback on the session. At the start and end of the M3 program, children will be asked to complete a feeling face questionnaire rated on a 3-point scale about topics discussed in the group such as how our brain works when upset and what is mindfulness.
Measure: Feasibility of Making Mindfulness Matter© (M3) as a family treatment for children with epilepsy and their parents Time: Throughout the study enrollment period and over the 8 weeks of intervention.Description: The Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55) is a 55-item measure that emphasizes a functional approach to quality of life. QOLCE-55 generates an overall quality of life score, and four subscale scores: cognitive, emotional, social and physical functioning. Scores range from 0 to 100, with higher scores indicative of better quality of life. Although the QOLCE is a widely used HRQOL scale, no study has calculated the minimum clinically important difference (MCID). To calculate the MCID for the QOLCE, the Patient Centred Global Ratings of Change will be used, a 5-item scale where respondents indicate the amount of change relative to baseline. Rating from -7 (much worse) through 0 (no change) to +7 (much better). This information will allow us to calculate the MCID for the QOLCE-55, and thereby identify the proportion of patients who experience a clinically meaningful change following intervention.
Measure: Effect of M3 on Health Related Quality of Life of children with epilepsy Time: baseline, 8 weeks, 17 weeksDescription: The Short Form Health Survey (SF12v2), a 12-item self-reported measure evaluating physical and mental health components of health-related quality of life over the past 4 weeks will be used. The measures generates two composite scales relating to the physical and mental health components of health related quality of life. This measure is the most frequently used patient reported outcome in clinical trials, and has been used most frequently in studies evaluating quality of life of parents of children with epilepsy.
Measure: Effect of M3 on Health Related Quality of Life of parents Time: baseline, 8 weeks, 17 weeksDescription: Behavior Assessment System for Children (BASC-3) 139-175-item comprehensive scale evaluating children's adaptive and problem behaviors in community and home settings. The BASC composite scale 'externalizing problems' will be used. Persons with T-score above 59 in a given scale are categorized as 'at-risk' for that domain.
Measure: Does M3 have a positive effect on children's externalizing problems Time: baseline, 8 weeks, 17 weeksDescription: Behavior Assessment System for Children (BASC-3) 139-175-item comprehensive scale evaluating children's adaptive and problem behaviors in community and home settings. The BASC composite scale 'internalizing problems' will be used. Persons with T-score above 59 in a given scale are categorized as 'at-risk' for that domain.
Measure: Does M3 have a positive effect on children's internalizing problems Time: baseline, 8 weeks, 17 weeksDescription: Behavior Assessment System for Children (BASC-3) 139-175-item comprehensive scale evaluating children's adaptive and problem behaviors in community and home settings. The BASC composite scale 'adaptive skills' will be used. Persons with T-score above 59 in a given scale are categorized as 'at-risk' for that domain.
Measure: Does M3 have a positive effect on children's adaptive skills Time: baseline, 8 weeks, 17 weeksDescription: Behavioral Rating Inventory of Executive Function 2 (BRIEF) 86-item scale measuring parent-rated executive function and self-regulation in children. Generates a global executive composite, cognitive regulation index, emotion regulation index, behavior regulation index. Persons with T-score above 60 in a given scale are categorized as 'at-risk' for that domain.
Measure: Does M3 have a positive effect on children's executive function Time: baseline, 8 weeks, 17 weeksDescription: Parents will rate the child's epilepsy severity using the Global assessment of the severity of epilepsy (GASE), a single item measure scale measured on a 7-point Likert type scale. Seizure frequency will be rated by parents through two questions asking the number of seizures and number of seizure-free days in the past 30 days.
Measure: Does M3 have a positive effect on children's severity of epilepsy Time: baseline, 8 weeks, 17 weeksDescription: Center for Epidemiological Studies Depression Scale (CES-D) 20-item scale evaluating the level of depressive symptoms, and is one of the most widely used instruments in the field of psychiatric epidemiology. Generates an overall score for depressive symptoms, with scores above 16 indicative of risk for depression.
Measure: Does M3 have a positive effect on parents' depression Time: baseline, 8 weeks, 17 weeksDescription: Generalized Anxiety Disorder 7-item (GAD-7) scale evaluating generalized anxiety. Generates an overall anxiety score, with scores above 10 indicative of moderate-severe anxiety.
Measure: Does M3 have a positive effect on parents' anxiety Time: baseline, 8 weeks, 17 weeksDescription: Parenting Stress Index 4 - short form 36-item scale that helps identify sources of stress. Focused on three major domains of stress: child characteristics, parent characteristics, and situational/demographic factors. A summary and 3 subscale (Parental Distress, Parent-Child Dysfunctional Interaction and Difficult Child) scores are generated. Scores in the 81st percentile or higher are indicative of high stress.
Measure: Does M3 have a positive effect on parents' stress Time: baseline, 8 weeks, 17 weeksThe purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsDescription: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 monthsThe purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsDescription: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 monthsThis is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, adjunctive therapy study in subjects with POS, with optional OLE. The study consists of 4 periods as follows: An 8-week of Screening/Baseline Period, 24-week of Double-blind Treatment Period (including a 18-week Titration Phase and 6-week Maintenance Phase), 52-week of Open-label Extension (OLE) Period (applicable for subjects who participate in the OLE) and up to 5-week of End of Study (EOS) Follow-up Period. The purpose of this study is to evaluate the efficacy and safety of 100, 200 and 400 mg/day of cenobamate as adjunctive therapy compared with placebo in subjects with partial onset seizures (POS). The study will also evaluate the long-term safety and tolerability of cenobamate adjunctive therapy in subjects with POS who have completed the double-blind treatment period.
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports